|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ATF7 |
Gene summary for ATF7 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ATF7 | Gene ID | 11016 |
| Gene name | activating transcription factor 7 | |
| Gene Alias | ATFA | |
| Cytomap | 12q13.13 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | P17544 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 11016 | ATF7 | LZE4T | Human | Esophagus | ESCC | 8.33e-06 | 1.78e-01 | 0.0811 |
| 11016 | ATF7 | LZE5T | Human | Esophagus | ESCC | 5.67e-03 | 2.33e-01 | 0.0514 |
| 11016 | ATF7 | LZE7T | Human | Esophagus | ESCC | 1.28e-08 | 3.44e-01 | 0.0667 |
| 11016 | ATF7 | LZE8T | Human | Esophagus | ESCC | 1.41e-02 | 6.48e-02 | 0.067 |
| 11016 | ATF7 | LZE20T | Human | Esophagus | ESCC | 1.52e-04 | 1.69e-01 | 0.0662 |
| 11016 | ATF7 | LZE22T | Human | Esophagus | ESCC | 6.65e-03 | 1.78e-01 | 0.068 |
| 11016 | ATF7 | LZE24T | Human | Esophagus | ESCC | 5.53e-12 | 3.42e-01 | 0.0596 |
| 11016 | ATF7 | LZE21T | Human | Esophagus | ESCC | 1.55e-03 | 1.04e-01 | 0.0655 |
| 11016 | ATF7 | P1T-E | Human | Esophagus | ESCC | 1.10e-08 | 3.13e-01 | 0.0875 |
| 11016 | ATF7 | P2T-E | Human | Esophagus | ESCC | 1.64e-25 | 5.50e-01 | 0.1177 |
| 11016 | ATF7 | P4T-E | Human | Esophagus | ESCC | 1.17e-21 | 4.11e-01 | 0.1323 |
| 11016 | ATF7 | P5T-E | Human | Esophagus | ESCC | 1.88e-13 | 1.94e-01 | 0.1327 |
| 11016 | ATF7 | P8T-E | Human | Esophagus | ESCC | 3.25e-24 | 4.23e-01 | 0.0889 |
| 11016 | ATF7 | P9T-E | Human | Esophagus | ESCC | 1.30e-12 | 3.16e-01 | 0.1131 |
| 11016 | ATF7 | P10T-E | Human | Esophagus | ESCC | 1.17e-25 | 2.38e-01 | 0.116 |
| 11016 | ATF7 | P11T-E | Human | Esophagus | ESCC | 5.33e-23 | 6.03e-01 | 0.1426 |
| 11016 | ATF7 | P12T-E | Human | Esophagus | ESCC | 7.44e-11 | 1.96e-01 | 0.1122 |
| 11016 | ATF7 | P15T-E | Human | Esophagus | ESCC | 6.95e-18 | 3.32e-01 | 0.1149 |
| 11016 | ATF7 | P16T-E | Human | Esophagus | ESCC | 1.99e-20 | 2.83e-01 | 0.1153 |
| 11016 | ATF7 | P17T-E | Human | Esophagus | ESCC | 2.40e-10 | 3.80e-01 | 0.1278 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00708972 | Oral cavity | OSCC | transcription preinitiation complex assembly | 24/7305 | 36/18723 | 7.18e-04 | 3.95e-03 | 24 |
| GO:20001423 | Oral cavity | OSCC | regulation of DNA-templated transcription, initiation | 26/7305 | 40/18723 | 7.79e-04 | 4.23e-03 | 26 |
| GO:000632510 | Oral cavity | OSCC | chromatin organization | 190/7305 | 409/18723 | 1.17e-03 | 5.97e-03 | 190 |
| GO:00434142 | Oral cavity | OSCC | macromolecule methylation | 149/7305 | 316/18723 | 1.82e-03 | 8.60e-03 | 149 |
| GO:00322591 | Oral cavity | OSCC | methylation | 168/7305 | 364/18723 | 3.03e-03 | 1.31e-02 | 168 |
| GO:00602602 | Oral cavity | OSCC | regulation of transcription initiation from RNA polymerase II promoter | 21/7305 | 33/18723 | 3.63e-03 | 1.51e-02 | 21 |
| GO:004325426 | Oral cavity | EOLP | regulation of protein-containing complex assembly | 112/2218 | 428/18723 | 1.58e-16 | 1.35e-13 | 112 |
| GO:003164726 | Oral cavity | EOLP | regulation of protein stability | 75/2218 | 298/18723 | 1.22e-10 | 1.35e-08 | 75 |
| GO:005082126 | Oral cavity | EOLP | protein stabilization | 51/2218 | 191/18723 | 1.37e-08 | 6.40e-07 | 51 |
| GO:003304422 | Oral cavity | EOLP | regulation of chromosome organization | 50/2218 | 187/18723 | 1.80e-08 | 7.94e-07 | 50 |
| GO:000632515 | Oral cavity | EOLP | chromatin organization | 84/2218 | 409/18723 | 2.68e-07 | 8.16e-06 | 84 |
| GO:200125222 | Oral cavity | EOLP | positive regulation of chromosome organization | 23/2218 | 82/18723 | 5.42e-05 | 7.00e-04 | 23 |
| GO:006096813 | Oral cavity | EOLP | regulation of gene silencing | 20/2218 | 81/18723 | 9.93e-04 | 7.46e-03 | 20 |
| GO:00400292 | Oral cavity | EOLP | regulation of gene expression, epigenetic | 24/2218 | 105/18723 | 1.07e-03 | 7.87e-03 | 24 |
| GO:20001422 | Oral cavity | EOLP | regulation of DNA-templated transcription, initiation | 11/2218 | 40/18723 | 5.53e-03 | 2.86e-02 | 11 |
| GO:00314532 | Oral cavity | EOLP | positive regulation of heterochromatin assembly | 5/2218 | 12/18723 | 8.97e-03 | 4.12e-02 | 5 |
| GO:01202632 | Oral cavity | EOLP | positive regulation of heterochromatin organization | 5/2218 | 12/18723 | 8.97e-03 | 4.12e-02 | 5 |
| GO:004325432 | Oral cavity | NEOLP | regulation of protein-containing complex assembly | 95/2005 | 428/18723 | 2.76e-12 | 5.29e-10 | 95 |
| GO:003164733 | Oral cavity | NEOLP | regulation of protein stability | 73/2005 | 298/18723 | 7.46e-12 | 1.17e-09 | 73 |
| GO:005082133 | Oral cavity | NEOLP | protein stabilization | 53/2005 | 191/18723 | 4.09e-11 | 5.41e-09 | 53 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ATF7 | MSC | Esophagus | Healthy | MAP2,ZNF554,NCK1-AS1, etc. | 9.64e-03 |  |
| ATF7 | CD8TEFF | Prostate | ADJ | DCAF17,VSIG10,NFYA, etc. | 2.58e-02 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ATF7 | SNV | Missense_Mutation | rs754866750 | c.733A>C | p.Ile245Leu | p.I245L | P17544 | protein_coding | tolerated(0.66) | benign(0) | TCGA-A2-A1G4-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | adriamycin | SD |
| ATF7 | SNV | Missense_Mutation | rs754866750 | c.733N>C | p.Ile245Leu | p.I245L | P17544 | protein_coding | tolerated(0.66) | benign(0) | TCGA-AN-A0XR-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| ATF7 | SNV | Missense_Mutation | rs754866750 | c.733A>C | p.Ile245Leu | p.I245L | P17544 | protein_coding | tolerated(0.66) | benign(0) | TCGA-B6-A1KN-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| ATF7 | SNV | Missense_Mutation | rs764112606 | c.896N>C | p.His299Pro | p.H299P | P17544 | protein_coding | deleterious(0.03) | benign(0.133) | TCGA-BH-A0B7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| ATF7 | SNV | Missense_Mutation | rs754866750 | c.733A>C | p.Ile245Leu | p.I245L | P17544 | protein_coding | tolerated(0.66) | benign(0) | TCGA-BH-A1FH-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| ATF7 | SNV | Missense_Mutation | rs754866750 | c.733A>C | p.Ile245Leu | p.I245L | P17544 | protein_coding | tolerated(0.66) | benign(0) | TCGA-C8-A273-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| ATF7 | SNV | Missense_Mutation | rs754866750 | c.733N>C | p.Ile245Leu | p.I245L | P17544 | protein_coding | tolerated(0.66) | benign(0) | TCGA-D8-A1JK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ATF7 | SNV | Missense_Mutation | rs754866750 | c.733A>C | p.Ile245Leu | p.I245L | P17544 | protein_coding | tolerated(0.66) | benign(0) | TCGA-D8-A1JT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| ATF7 | SNV | Missense_Mutation | rs754866750 | c.733A>C | p.Ile245Leu | p.I245L | P17544 | protein_coding | tolerated(0.66) | benign(0) | TCGA-D8-A1XG-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| ATF7 | SNV | Missense_Mutation | c.61N>C | p.Glu21Gln | p.E21Q | P17544 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-E2-A1L7-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |